Join us as a panel of experts discusses challenges in developing, launching and commercialising ATMPs in Europe. The panel of industry leaders will also share insights into which specific requirements have to be met to ensure the progress of European cell and gene therapy.
Eureka Therapeutics has received a $10.6 million grant from the California Institute for Regenerative Medicine (CIRM) to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of refractory/relapsed liver cancer for pediatric patients.
UK-based independent innovation and technology organization Cell and Gene Therapy Catapult (CGT Catapult), has officially opened new laboratories and offices in Edinburgh, Scotland, UK, BioQuarter – enhancing Edinburgh’s role as a hub for cell therapies.
Join the discussion uncovering the advantages of AAV analytics when using the right in-process controls and standards to ensure comparability and perform proper safety & efficacy evaluations
BioCentriq launched their new LEAP™ Advanced Therapy Platform at the 29th International Society for Cell & Gene Therapy (ISCT) annual event with proven assets and expertise to help early-stage biotech companies effectively deliver to patients without compromising quality.
As manufacturing pipelines scale in line with increased demand for advanced therapies, there is further demand for digital solutions to support complex manufacturing process development.
This Case Study demonstrates how the Association for the Advancement of Blood & Biotherapeutics (AABB) evaluated the apparent challenges in identifying and retaining employees due to a shortage in the worldwide biotherapies workforce.
Gene-edited cell therapies represent a rapidly growing area for advanced therapeutic development, but manufacturing-related challenges remain to commercialize such complex therapies.
This Case Study demonstrates how the Excellos team successfully carried out process development of a scale up procedure from tissue culture stacks to a commercial bioreactor system.
This Case Study demonstrates how the use of Akadeum’s microbubble platform offers a simple and highly tunable isolation and activation workflow that generates T cells ready for suspended cell culture and downstream applications, such as genetic modification and expansion, and discusses the potential impact of the solution on cancer treatment.
The Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for gene therapy development.
As we celebrate 10 years of CAR-T, the Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for CAR-T development.
Gaining market and patient access in Europe has presented many cell and gene therapy companies with barriers. The advanced therapies industry is currently facing a dilemma: scientific advancement is exceeding market and reimbursement adaptation.